ENTITY
SciClone Pharmaceuticals

SciClone Pharmaceuticals (SCICLONE HK)

108
Analysis
Health Care • China
SciClone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for oncology and severe infection in Mainland China and internationally. Its portfolio includes proprietary product Zadaxin, used for hepatitis B, hepatitis C, and certain cancers, as well as in-licensed products like Zometa, DANYELZA, and Angiomax. The company was founded in 1990 and is headquartered in Shanghai, China.
more
bullish•Infocom Corp
•02 Jun 2024 02:29

Weekly Deals Digest (02 Jun) - Infocom, CF Logistics, Asia Cement, GA Pack, Huafa, Shift Up

Last week, notable developments occurred in Event-Driven (Infocom, CF Logistics, Asia Cement China, GA Pack, Huafa, SciClone, Adbri) and ECM (Shift...

Logo
689 Views
Share
bullish•BHP Group Ltd
•01 Jun 2024 15:00

(Mostly) Asia-Pac M&A: Huafa Prop, Asia Cement, QV Equities, Sciclone, Chilled & Frozen Logistics

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
688 Views
Share
•30 May 2024 07:48

SciClone Pharmaceuticals (6600 HK): 19th June Shareholder Vote

This is positive. Pentwater Capital with 8.51% of independent shares (& 4.64% of shares out), has confirmed it will vote for the Scheme at the 19th...

Logo
849 Views
Share
•29 May 2024 21:57

SciClone Pharma (6600 HK): Scheme Vote on 19 June

SciClone has received a letter of support from Pentwater Capital Management to vote YES. Pentwater represents 4.64% of out. shares and 8.51% of...

Logo
913 Views
Share
•27 May 2024 22:22

Huafa Property Services (982 HK): Scheme Offer at HK$0.29

The offer, which has been declared final, is attractive compared to historical share prices and peer multiples. This is a done deal, with payment...

Logo
483 Views
Share
x